Alzheimer's disease is characterized by the hallmark pathology of beta-amyloid plaque and tau protein tangles, but there appears to be a new protein on the block in the development of the neurodegenerative disease. It is called TAR DNA binding protein of 43kDa (TDP-43), according to research presented during the 2014 international conference of the Alzheimer's Association (AAIC).

Finding tau deposition in the brain could be a way to verify Alzheimer's prior to the arrival of all the characteristic symptoms, according to a study presented during this week's Alzheimer's Association International Conference (AAIC) 2014.

The amyloid PET agent F-18 flutemetamol (Vizamyl) was the topic of two scientific sessions at the Alzheimer’s Association International Conference (AAIC), which concluded yesterday in Copenhagen. Results of one study showed improvements in clinical decision making and clinician confidence as a result of information gleaned from flutemetamol PET. In another study, patients with mild cognitive impairment (MCI) whose scans were positive for flutemetamol were 2.5 times more likely to progress to Alzheimer's disease.

IBA announced this week that the FDA has provided marketing authorization for the gantry beam line designed for the company’s compact proton therapy system, which will be used much like its larger cousins for the treatment of a variety of cancers.

NorthStar Medical Radioisotopes announced July 16 that the company had broken ground on the 50,000-square-foot production facility and headquarters in Beloit, Wis.

From age 7 months to 12 months, babies undergo a huge transition in language development. Researchers from the University of Washington are now conducting the most detailed look at neural activity when infants listen to speech using magnetoencephalography.

In a recent Health Imaging cover story, we looked at the changing demographics of the U.S. and the impact an aging population will have on the rates of a variety of conditions such as Alzheimer's disease. There is some good news that is being masked by these projections, however, as research revealed this week at Alzheimer’s Association International Conference showed. 

A cutting-edge detector developed by researchers in the United Kingdom and South Africa stands to spark more effective proton therapy for cancer patients.